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Profile of tildrakizumab-asmn in the treatment of 
moderate-to-severe plaque psoriasis: evidence to 
date
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eric J Yang 
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Department of Dermatology, 
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Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults 
in the United States. Advances over the past 20 years in understanding the immune-mediated 
pathophysiology of psoriasis have led to the development of targeted biologic therapies for this 
condition. Currently, biologic medications approved for the treatment of plaque psoriasis include 
tumor necrosis factor α inhibitors, interleukin (IL)-17 or IL-17 receptor inhibitors, IL-12/23 
inhibitors, and IL-23 inhibitors. Tildrakizumab-asmn is a monoclonal antibody that targets the 
p19 subunit of IL-23 and is approved for use in adult patients with moderate-to-severe plaque 
psoriasis who are candidates for systemic therapy or phototherapy. This article reviews the cur-
rent pharmacologic, efficacy, and safety data on tildrakizumab-asmn.
Keywords: tildrakizumab, IL-23, IL-23p19, biologics, psoriasis
Introduction
Plaque psoriasis is a chronic, immune-mediated skin disease that affects roughly 3% 
of adults in the United States.1 Psoriasis may have significant disease comorbidities 
and a substantial negative impact on quality of life.2 Mild or localized psoriasis may 
be managed with topical treatments, whereas systemic or biologic therapies are war-
ranted for more severe or widespread disease.3 The development of targeted biologic 
therapies as a systemic treatment option for psoriasis is a result of advances in the 
understanding of the immune-mediated pathophysiology of psoriasis over the past 
20 years.4 Currently, biologic medications approved for the treatment of plaque psoriasis 
include tumor necrosis factor alpha (TNF-α) inhibitors, interleukin (IL)-17 and IL-17 
receptor (IL-17R) inhibitors, IL-12/23 inhibitors, and IL-23p19 inhibitors. The newest 
psoriasis treatment options approved by the US Food and Drug Administration (US 
FDA) are the anti-IL-17 biologics secukinumab (Cosentyx®, Novartis International AG, 
Basel, Switzerland) and ixekizumab (Taltz®, Eli Lilly and Co., Indianapolis, IN, USA), 
the anti-IL-17R biologic brodalumab (Siliq®, Valeant Pharmaceuticals, Bridgewater 
Township, NJ, USA), and the anti-IL-23p19 biologics guselkumab (Tremfya®, Janssen, 
Beerse, Belgium) and tildrakizumab-asmn (Ilumya®, Sun Pharmaceuticals, Mumbai, 
India). This review will focus on the most current evidence for tildrakizumab-asmn.
Rationale for the targeting of IL-23p19 to treat 
psoriasis
Although the pathophysiology of psoriasis is complex and incompletely understood, 
recent evidence that the IL-23/IL-17 axis plays a key role in psoriasis has led to the 
Correspondence: Kristen M Beck
Department of Dermatology, University 
of California San Francisco, 515 Spruce 
Street, San Francisco, CA 94118, USA
Tel +1 415 476 4701
Fax +1 415 502 4126
Email Kristen.Beck@ucsf.edu
Journal name: Psoriasis: Targets and Therapy
Article Designation: Review
Year: 2018
Volume: 8
Running head verso: Beck et al
Running head recto: Tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis
DOI: http://dx.doi.org/10.2147/PTT.S146640
Psoriasis: Targets and Therapy 2018:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
50
Beck et al
development of biologic treatments that target this pathway 
specifically.5,6 IL-23 is a heterodimeric cytokine consisting 
of a p19 and a p40 subunits, predominantly expressed by 
macrophages and dendritic cells.7,8 The p40 subunit of IL-23 
is shared with IL-12, and is the target of another biologic 
for psoriasis, ustekinumab (Stelara®, Janssen). Recent stud-
ies suggest that targeting IL-23 alone may result in a more 
favorable risk–benefit profile in comparison to targeting 
both IL-23 and IL-12.9 While IL-23 appears critical for 
IL-17 differentiation,6 IL-12 is implicated in a host of other 
processes in the body, including host defense against infec-
tion and malignancy.10 For this reason, the p19 subunit of 
IL-23, which is not shared with IL-12, became a target of 
drug development.11
IL-23 is implicated as a “master cytokine” in inflamma-
tory skin disease because it induces differentiation of type 
17 helper T lymphocytes (Th17 cells), which in turn secrete 
pro-inflammatory cytokines, including IL-17A, IL-17F, and 
IL-22.8 This results in increased keratinocyte proliferation 
and differentiation, which clinically presents as psoriatic 
epidermal hyperplasia.12,13 Further evidence for the role of 
IL-23 in psoriasis comes from messenger RNA data, which 
show the overexpression of IL-23p19 and IL-12/23p40 in 
psoriatic skin.14 Favorable results from clinical trials test-
ing new molecules targeting the IL-23p19 subunit further 
validate the important role of IL-23 in moderate-to-severe 
plaque psoriasis.10
The first FDA approved biologic of the IL-23p19 class was 
guselkumab (Tremfya®, Janssen), which was approved in July 
2017. Tildrakizumab was approved in 2018. Risankizumab 
(BI 655066, AbbVie),15 a third IL-23p19 inhibitor, is currently 
in advanced stages of clinical evaluation.
Tildrakizumab
Tildrakizumab-asmn (tildrakizumab) is a humanized (from 
mouse) IgG1κ monoclonal antibody that selectively inhib-
its the p19 subunit of IL-23 and neutralizes its function 
(Figure 1). The suffix “-asmn” is used to differentiate this 
originator biologic from future biosimilar versions of tildraki-
zumab.16 In March 2018, tildrakizumab was approved by the 
US FDA for use in adult patients with moderate-to-severe 
plaque psoriasis who are candidates for systemic therapy 
or phototherapy.17 It is recommended to evaluate patients 
for tuberculosis infection prior to initiating treatment. Til-
drakizumab treatment may increase the risk of infection. 
The use of live vaccines is contraindicated for patients on 
tildrakizumab. Tildrakizumab is contraindicated in patients 
with a hypersensitivity reaction to tildrakizumab or to any 
of its excipients.
FDA approval for tildrakizumab was based on pooled data 
from three placebo-controlled clinical trials in which a total 
of 705 subjects received tildrakizumab at the FDA-approved 
dosing schedule.17 Tildrakizumab is given by subcutaneous 
(SC) injection at a dose of 100 mg every 12 weeks, after 
the completion of initiation dosing, which consists of 100 
mg at week 0 and week 4. Tildrakizumab is available in 
prefilled syringes, each containing 1 mL of 100 mg/mL of 
the antibody.
With regard to immunogenicity, ~6.5% of study par-
ticipants treated with 100 mg tildrakizumab developed 
IL-23 P19
Macrophage
Dendritic
cell
TNF-
Inflammation
IL-17
Th17
Th17
precursorIL23/
IL12RB1
receptor
Tildrakizumab
P40
Psoriasis
Figure 1 The mechanism of action of tildrakizumab.
Notes: Tildrakizumab selectively inhibits the p19 subunit of IL-23 and neutralizes its function.
Abbreviation: IL, interleukin; Th17, type 17 helper T lymphocytes; TNF-α, tumor necrosis factor alpha.
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antibodies to tildrakizumab.17 Of these, ~40% developed 
neutralizing antibodies, which were associated with lower 
serum concentrations of tildrakizumab and reduced efficacy.
Pharmacologic parameters of 
tildrakizumab
Pharmacokinetic studies of tildrakizumab in plaque pso-
riasis show that both the maximum concentration (C
max
) 
and the area under the curve (AUC) increase proportion-
ally from doses of 50 to 200 mg or 0.1 to 10 mg/kg (0.5–2 
times the FDA-approved recommended SC dosage).17 The 
bioavailability of tildrakizumab is ~73%–80% following 
SC injection. The peak plasma concentration is 8.1 µg/mL, 
with a peak plasma time of ~6 days. Steady-state concentra-
tions were achieved in week 16 following subcutaneously 
administered tildrakizumab at a dose of 100 mg, which is 
the approved recommended dosage. The mean steady-state 
trough concentrations ranged from 1.22 to 1.47 (SD), ±0.94 
and ±1.12 µg/mL). The geometric mean steady-state C
max
 
was 8.1 µg/mL or 34%. Tildrakizumab concentrations were 
lower in subjects with higher body weight, though there is no 
indication for weight-based dose adjustments. The half-life 
(t
1/2
) is ~ 20.2–28.2 days. The volume of distribution is 10.8 
L. Clearance occurs at a rate of 0.32 L/day (38%).
Per US prescribing information, no formal pharmaco-
dynamic studies have been conducted for tildrakizumab.17 
Metabolism of tildrakizumab is also not characterized. 
However, the medication is expected to degrade into small 
peptides and amino acids through catabolic pathways, similar 
to endogenous IgG. The effects of renal and hepatic impair-
ment on tildrakizumab have not been studied. Tildrakizumab 
has not been studied in special populations such as geriatric, 
pediatric, breastfeeding, or pregnant populations.
Clinical trials
The remainder of this article will review the clinical trial data 
for tildrakizumab in further detail (Table 1).
Phase i
An exploratory, proof-of-concept, three-part, multiple-dose, 
randomized, placebo-controlled patient- and evaluator-blind, 
multi-center Phase I study of tildrakizumab was performed 
to determine the safety, tolerability, and pharmacokinetics 
of intravenous (IV) tildrakizumab at rising doses in adults 
with moderate-to-severe psoriasis.13 A secondary objective 
of the trial was to evaluate the efficacy of tildrakizumab on 
psoriatic skin disease.
A total of 77 subjects were enrolled in this Phase I study. 
The study subjects included males (61/77, 79%) and females 
(16/77, 21%) who were predominantly white (69/77, 90%), 
ranging from 22 to 65 years of age (mean age of 47.3, SD 
11.4), and mean weight of 97.67 kg (SD 20.23).
Part 1 of this trial examined safety, tolerability, and 
pharmacokinetics of four ascending doses of IV injections of 
tildrakizumab in 24 subjects divided into four ascending dose 
cohorts. The subjects were randomized to receive 0.1 mg/kg 
(n=3), 0.5 mg/kg (n=3), 3 mg/kg (n=6), or 10 mg/kg (n=6) 
tildrakizumab, or placebo dose (n=6) at weeks 0, 8, and 12. 
Subjects were followed up for 196 days after the first dose.
Part 2 examined the efficacy of higher doses of IV til-
drakizumab in a larger number of subjects. Forty subjects 
received three doses of either 3 mg/kg (n=15) or 10 mg/kg 
(n=14) of IV tildrakizumab or placebo (n=11) given at weeks 
0, 4, and 8. Subjects were followed up for 364 days after the 
first dose.
Part 3 evaluated the efficacy of lower doses of IV tildraki-
zumab. Twelve subjects were randomized in a 2:1:1 ratio to 
receive 0.05 mg/kg IV tildrakizumab (n=6), 0.1 kg/mg IV 
tildrakizumab (n=3), or placebo (n=3) at weeks 0, 8, and 12. 
Three treatments were administered in a parallel fashion at 
weeks 0, 8, and 12.
The primary efficacy end point was the percentage change 
in Psoriasis Area and Severity Index (PASI) score from base-
line at 4 or 8 weeks after the last treatment day (week 16 for 
parts 1, 2, and 3). Throughout the study, study subjects were 
monitored by safety assessments that included vital signs, 
ECGs, clinical laboratory measurements, and adverse event 
(AE) screening. PASI scores were determined at screening, 
baseline, and throughout the study at specified intervals 
until day 112 in part 1, and day 364 in parts 2 and 3. Serum 
pharmacokinetic samples were collected at specified intervals 
Table 1 Clinical trials of tildrakizumab for plaque psoriasis
Clinical trial Phase Reference Total 
number of 
patients 
enrolled
Tildrakizumab 
therapeutic 
dosing 
regimen
Protocol 05,382 i Kopp et al, 
201513
77 0.1, 0.5, 3, or 
10 mg/kg IV
NCT01225731 IIb Papp et al, 
201510
355 5, 25, 100, or 
200 mg SC
reSURFACE 1 iii Reich et al, 
201719
772 100 or 200 mg 
SC
reSURFACE 2 iii Reich et al, 
201719
1,090 100 or 200 mg 
SC
Abbreviations: IV, intravenous; SC, subcutaneous.
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in all three parts of the study. Pre-dose (within 3–7 days of 
initial dose) and post-dose biopsies (4 weeks after the last 
dose) were obtained from a subset of subjects treated with 
placebo (n=5), 3 mg/kg of tildrakizumab (n=10), 10 mg/kg 
of tildrakizumab (n=7), and healthy volunteers (n=5) for 
exploratory histological, immunohistochemical, and gene 
expression analyses. Skin biopsies were also assessed using 
a Histopathological Psoriasis Severity Score (HPSS),18 in 
order to quantify the overall global effect of tildrakizumab on 
the epithelium, vasculature, and infiltrates of psoriatic skin.
Results
Pharmacodynamics
Tildrakizumab showed dose-related efficacy in the treatment 
of plaque psoriasis. Subjects treated with IV tildrakizumab 
0.05–10 mg/kg had a mean (placebo-corrected) PASI score 
reduction of 50%–80% by week 14 (day 112), which sus-
tained through week 28 (day 196). A majority of subjects 
on 3 or 10 mg/kg doses achieved PASI 75, with a large 
proportion achieving PASI 90, by day 112. Subjects treated 
with 3 or 10 mg/kg of IV tildrakizumab maintained at least 
PASI 50 by week 44 (day 308, 36 weeks after the last dose), 
whereas those in part 3 treated with 0.05 or 0.1 mg/kg did 
not. However, this Phase I study was not sufficiently powered 
to show a clear dose–response.
Safety and tolerability
Overall, IV tildrakizumab was well tolerated in all doses 
evaluated. The maximum dose evaluated was 10 mg/kg IV 
once monthly. The most common AEs included headache 
(tildrakizumab-treated: 11/57 [19%], placebo: 3/20 [15%], 
upper respiratory infection: 11/57 [19%] and 3/20 [15%], 
nasopharyngitis: 10/57 [18%] and 2/20 [10%], and cough: 
9/57 [16%] and 3/20 [15%]). Of the eleven SAEs reported in 
eight subjects, ten were thought to be unrelated to treatment 
and one SAE was deemed possibly related to treatment (con-
vulsions in a subject who received 10 mg/kg tildrakizumab 
17 days prior).
Pharmacokinetics
Based on the cumulative results of parts 1, 2, and 3, the 
mean half-life (t
1/2
) of tildrakizumab ranged from 20.2 to 
26.9 days. For doses of 0.05–10 mg/kg, the mean clearance 
ranged from 1.57 to 2.50 mL/day. No dose-related trends were 
observed for either half-life or clearance. Using a one-way 
analysis of variance dose proportionality test in part 2 only, 
dose proportionality for the AUC and C
max
 was shown for 3 
and 10 mg/kg doses of tildrakizumab. Tildrakizumab also 
demonstrated linear exposure over the administered doses.
Immunogenicity
A majority of the tildrakizumab-treated subjects tested nega-
tive for antidrug antibodies prior to treatment (n=51). After 
tildrakizumab treatment, 18% (9/51) of the pretreatment 
ADA-negative subjects had at least one posttreatment ADA-
positive sample. Fifty-six percent (5/9) of these subjects 
showed lower tildrakizumab exposure than ADA-negative 
subjects. There was no difference in PASI response or AEs 
reported in subjects with ADA-positive samples.
Exploratory histological, 
immunohistochemical, and gene 
expression analyses
After treatment with tildrakizumab, epithelial hyperplasia 
in the psoriatic lesions improved to the levels found in non-
lesional skin (as measured by a decrease in epithelial thick-
ness), but not fully to that of normal, healthy skin. There was a 
significant reduction in the total HPSS (mean reduction 67%, 
95% CI: 53%–81%). The HPSS was significantly reduced 
in both the 3 and 10 mg/kg treated groups (pre- and post-
dose HPSS 16.5±1.3 [mean ± SEM] to 6.2±61.9 [P<0.01] 
and 20.0±2.5–4.4±1.2 [P<0.05], respectively). Each of the 
epithelial, vascular, and inflammatory cell parameters was 
significantly reduced after tildrakizumab treatment (P<0.01 
for the epithelial score of 3 mg/kg, P<0.05 for all others), 
whereas reductions for these parameters in the placebo group 
were not significant.
Post-dose biopsies showed significant reduction mitosis 
within the suprabasal epidermal layer, as measured by cell 
proliferation (Ki67+ cells per mm) and keratinocyte differen-
tiation (keratin 16 score) after treatment with tildrakizumab, 
but not with placebo.
The levels of inflammatory infiltrate of psoriatic skin 
lesions significantly decreased after treatment with tildraki-
zumab. Specifically, epidermal CD4+ and CD8+ T cells, as 
well as dermal myeloid dendritic cells, plasmacytoid dendritic 
cells, and CD15+ neutrophils were significantly reduced after 
three doses of 10 mg/kg tildrakizumab (P<0.05). Epidermal 
CD4+ T cells, dermal plasmacytoid dendritic cells, and neu-
trophils, but not epidermal CD8 T cells or dermal myeloid 
DCs, decreased after three doses of 3 mg/kg tildrakizumab 
(P<0.01). Langerhans cells were not significantly increased in 
psoriatic skin lesions at baseline, nor were they significantly 
reduced after tildrakizumab treatment.
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IL-23p19 expression decreased to nearly undetectable 
levels after treatment with tildrakizumab, though the reduc-
tion was not significant as compared to placebo.
IL-23-associated psoriatic skin gene expression (IL-19, 
IL-20, S100A7, LCN2, CCL20, and CXCL8) was signifi-
cantly reduced in skin biopsies of subjects treated with at 
least one dose of 3 or 10 mg/kg tildrakizumab (P<0.05), but 
not in the subjects treated with placebo. The decreases in 
gene expression correlated with decreased epithelial thick-
ness (mm), decreased keratinocyte proliferation (measured 
by Ki67 cells per mm), normalized keratinocyte differentia-
tion (measured by keratin 16 score), and reduced CD4 T cell 
and neutrophil infiltrates after treatment with tildrakizumab.
Phase ii
A three-part, Phase IIb, randomized, double-blinded, placebo-
controlled, parallel-design study of subcutaneously adminis-
tered tildrakizumab (NCT01225731) in adult subjects with 
moderate-to-severe chronic plaque psoriasis clinical trial was 
performed at 64 sites in the United States, Canada, Europe, 
and Japan.10
This Phase II trial enrolled 355 subjects, and 266 sub-
jects completed the study. Study participants were men and 
women with baseline moderate-to-severe plaque psoriasis 
(PASI ≥12; BSA ≥10; PGA of moderate, marked, or severe) 
for at least 6 months.
In part 1 (weeks 0–16) of this trial, subjects were ran-
domized in a 1:2:2:2:1 ratio to receive SC injections of 
tildrakizumab at doses of 5 mg (n=42), 25 mg (n=92), 100 
mg (n=89), or 200 mg (n=86) or placebo (n=46). Doses were 
administered at weeks 0 and 4. At the end of part 1, subjects 
were assessed for their responder status (based on week 16 
PASI response) in order to determine their treatment for part 
2. Responders had at least a 75% reduction in PASI score 
from baseline.
During part 2 (weeks 16–52), all subjects received active 
treatment with tildrakizumab. Subjects on placebo in part 
1 were started on 100 mg of tildrakizumab in part 2. Non-
responders in the 5 and 25 mg groups were increased to 100 
mg, while those in 100 mg groups were increased to 200 
mg, and those in the 200 mg group remained at that dose. 
Responders on 5 or 25 mg tildrakizumab continued at their 
same doses through week 52. Responders on 200 or 100 
mg of tildrakizumab were re-randomized to either continue 
their current dose or switch to a reduced dose of 100 or 25 
mg, respectively.
Part 3 (weeks 52–72) consisted of a follow-up period 
after treatment was discontinued at week 52.
The primary efficacy end point was a reduction in PASI 
score of at least 75% from baseline to week 16. The impact 
on quality of life was monitored by use of the Dermatology 
Life Quality Index (DLQI). Periodic blood sampling was 
performed to evaluate the pharmacokinetics and development 
of ADA to tildrakizumab. AEs, ECG, clinical safety, and vital 
signs were monitored throughout the study.
Results
Clinical efficacy
At week 16, PASI 75 responses were achieved in 33%, 64%, 
66%, and 74% of patients in the 5 mg (n=42), 25 mg (n=90), 
100 mg (n=89), and 200 mg (n=86) tildrakizumab dose 
groups, respectively, compared to 4.4% for placebo (P≤0.001 
for each active treatment group compared to placebo). In 
addition, PASI 90 at week 16 was achieved in 12%, 25%, 
39%, and 52% of the tildrakizumab groups, respectively. The 
median time to PASI 75 was 85 days in the 25 mg group, 84 
days in the 100 mg group, and 57 days in the 200 mg group 
(P≤0.001 compared to placebo). PASI 75 response rates at 
week 12 were 61% (n=54/89) in the 100 mg group and 72% 
(n=62/82) in the 200 mg group, compared to 4.4% for placebo 
(n=2/45) (P≤0.001 for each treatment group vs placebo).
Of the responders at week 16, results from part 2 of the 
study showed that PASI 75 response was maintained at week 
52 in 97% of subjects who continued on doses of 100 mg 
(n=30/31) or 200 mg (n=29/32) throughout parts 1 and 2, 
compared to 70% of those who received a dose reduction from 
100 to 25 mg (n=21/30). In part 2, there was a significant loss 
in efficacy in those who received a reduction from 100 to 25 
mg compared to those who remained on 100 mg (P<0.005). 
There was no significant difference in those who remained on 
200 mg in parts 1 and 2 compared to those who were decreased 
from 200 to 100 mg in part 2; PASI 75 was maintained at week 
52 in 97% (29/32) and 85% (27/32), respectively.
In part 3, PASI 75 was maintained 20 weeks after study 
drug discontinuation in 96% of subjects on 100 mg and 
93% on 200 mg tildrakizumab, in contrast to 68% of those 
whose dose was reduced from 200 to 100 mg at week 16. 
Eight subjects with a week 52 PASI 75 response experienced 
relapse in part 3 (25 mg, n=4; 100 mg, n=3; 200 mg, n=1).
Pharmacokinetics
The mean concentration of tildrakizumab was usually higher 
in responders than in nonresponders, and increased propor-
tionally with dose. The exposure in the groups receiving 200 
mg of tildrakizumab (the highest dose studied) was similar 
for both responders and nonresponders.
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Immunogenicity
Of the 355 subjects enrolled, 46 had positive baseline ADA 
assays performed prior to receiving tildrakizumab. Of the 
subjects with baseline negative ADA screening, 25 developed 
at least one positive ADA after receiving a dose of tildraki-
zumab, and 10 of these 25 tested positive for neutralizing 
antibodies. Sixteen of the 46 (35%) subjects with positive 
ADA screens had qualitatively reduced tildrakizumab levels. 
The development of neutralizing antibodies did not appear 
related to the development of AEs.
Safety profile
Out of all randomized participants who received one or 
more doses of treatment, AEs were reported at a rate of 
65%, 66%, and 40% in parts 1, 2, and 3, respectively. In 
all treatment arms, the overall incidence of AEs was gen-
erally similar and did not differ from placebo. No signifi-
cant, clinically meaningful differences in clinical safety, 
ECGs, or vital signs were observed in patients receiving 
tildrakizumab compared with placebo. The most frequently 
reported AEs in parts 1–3 were nasopharyngitis and 
headache. There was a low rate of AEs of special interest, 
including serious infections, malignancy, major cardiovas-
cular events, drug-related hypersensitivity, and drug-related 
injection site reactions. A total of 23 subjects reported 
SAEs (part 1, n=4; part 2, n=14, part 3, n=5). SAEs thought 
to be related to tildrakizumab treatment included bacterial 
arthritis, lymphedema, melanoma, stroke, epiglottitis, and 
knee infection. There was one death in the study, thought 
to be unrelated to study treatment. The study concluded 
that tildrakizumab was well tolerated and generally safe 
for 52 weeks of treatment.
Quality of life
The mean change in DLQI score from baseline to week 16 
was –4.9, –9.2, –8.5, and –8.8 in the 5, 25, 100, and 200 
mg tildrakizumab groups, respectively, compared with 1.0 
in the placebo group. A DLQI score of 0 or 1 at week 16 
was achieved by 32%, 57%, 52%, and 57% of patients in 
the tildrakizumab groups, respectively, compared to 0% in 
the placebo group. A 5-point reduction from baseline DLQI 
score at week 16 occurred in 52%, 70%, 65%, and 73% of 
the 5–200 mg tildrakizumab groups, respectively, compared 
with 19% of the placebo group. Symptoms/Feelings and 
Daily Activities were the DLQI subcategories that were 
most improved after treatment. Overall, the improvement in 
quality of life correlated to the clinical improvement in each 
treatment group.
Phase III (reSURFACE 1 and 
reSURFACE 2)
Tildrakizumab demonstrated efficacy in patients with moder-
ate-to-severe chronic plaque psoriasis in two pivotal Phase III, 
three-part, parallel group, randomized, double-blind clinical 
trials, reSURFACE 1 (NCT01722331) and reSURFACE 2 
(NCT01729754).19 Based on data from the Phase IIb trial,10 
dosing consisted of 100 or 200 mg of tildrakizumab given 
subcutaneously at weeks 0 and 4 (initiation therapy) and every 
12 weeks thereafter (maintenance therapy). Tildrakizumab 
was compared with placebo in reSURFACE one and placebo 
or etanercept in reSURFACE 2.19
Participants in reSURFACE 1 (N=772) and reSURFACE 
2 (N=1090) were 18 years of age or older with moderate-to-
severe psoriasis, as defined by BSA ≥10% or PASI ≥12, and 
were considered candidates for phototherapy or systemic 
therapy. The baseline demographics of the study participants 
were similar in all groups; the majority were white males, 
with an average age of 44–48 years, who had not previously 
been on biologic therapy.19 The most common previous 
medical condition in these patients was hypertension. The 
average baseline PASI score was around 20, with roughly 
30% BSA involvement.19
Part 1 of both studies comprised the first 12-week treat-
ment period. In reSURFACE 1, study subjects were random-
ized in a 2:2:1 ratio to tildrakizumab 200 mg, tildrakizumab 
100 mg, or placebo at weeks 0 and 4. In reSURFACE 2, study 
subjects were randomized in a 2:2:1:2 ratio to tildrakizumab 
200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 
mg twice weekly.
Part 2 was a 16-week period (weeks 12–28) in which 
the placebo group in each study was re-randomized in a 1:1 
ratio to tildrakizumab 200 or 100 mg starting with initiation 
dosing at week 12, while tildrakizumab groups continued 
maintenance dosing, with their next dose at week 16. In 
reSURFACE 2, the etanercept group received one dose 
weekly. Subjects from all groups who had a PASI response 
of <50% (non-responders) at week 28 were discontinued so 
as to maintain masking.19
In part 3, subjects in both studies received either tildraki-
zumab or placebo until week 64. At week 28 in reSURFACE 
1, tildrakizumab 200 and 100 mg responders (PASI ≥75) 
and partial responders (PASI ≥50 to PASI <75) were re-
randomized to continue the same treatment, switch to a dif-
ferent dose of tildrakizumab, or switch to placebo. Subjects 
who experienced relapse on placebo or a different dose were 
re-treated with tildrakizumab upon relapse. In reSURFACE 2, 
part 3 also evaluated etanercept non-responders (PASI ≤50) 
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and partial responders (PASI ≤50–75) at week 28 who were 
switched to tildrakizumab 200 mg until week 52. The dura-
tion of part 3 was 36 weeks (week 28–64) in reSURFACE 1 
and 24 weeks (weeks 28–52) in reSURFACE 2. An optional 
long-term safety extension study of 4 years duration was 
then performed, followed by a follow-up/washout period of 
20 weeks.
Study assessments included clinical response evaluations 
(PASI, PGA), safety evaluations, and quality of life measures 
(DLQI) throughout the study. Efficacy and safety measure-
ments were done at baseline and weeks 4, 8, 12, 16, 22, and 
28 in parts 1 and 2. In part 3, efficacy was assessed at weeks 
32, 36, 40, 46, and 52 in both studies, and efficacy and safety 
were assessed at week 64 in reSURFACE 1.
The primary objective of the reSURFACE studies was 
to evaluate the efficacy and safety of tildrakizumab after 12 
weeks. The primary efficacy endpoint was the proportion 
of patients achieving PASI 75 at week 12, for both the 100 
and 200 mg doses, as compared to placebo. The co-primary 
endpoints were the proportion of patients achieving PASI 75 
and PGA scores of “clear” or “minimal” with at least a two-
grade reduction from baseline at week 12. In reSURFACE 
2, PASI 75 and PGA responses at week 28 were also key 
secondary endpoints. The PASI 75 response in patients 
receiving continuous treatment with tildrakizumab from 
baseline to the end of week 64 in reSURFACE 1 or week 52 
in reSURFACE 2 was also assessed as a secondary outcome. 
An additional secondary endpoint in both studies was the 
proportion of subjects with a DLQI score of either 0 or 1 by 
weeks 12 and 28.
Results
Clinical efficacy
The efficacy results from both the doses of tildrakizumab 
evaluated in the reSURFACE trials are summarized in 
Table 2. The efficacy data of the FDA-approved tildrakizumab 
(100 mg) as compared to placebo or placebo and etanercept 
are summarized in Table 3. In patients treated with 100 mg 
of tildrakizumab, 64% of subjects in reSURFACE 1 (n=197) 
and 61% (n=188) of patients in reSURFACE 2 achieved PASI 
75 at week 12, compared to 6% (n=9) or 6% (n=9) and 48% 
(n=313), compared to placebo in reSURFACE 1 or compared 
to placebo and etanercept in reSURFACE 2, respectively. The 
results were significant (P<0.001) for comparisons of each 
Table 2 Phase III efficacy data of tildrakizumab from reSURFACE 1 and reSURFACE 2
Clinical 
clearance 
metric
reSURFACE 119 reSURFACE 219
200 mg 100 mg 200 mg 100 mg PBO→200 mg PBO→100 mg
N=308 N=309 N=314 N=307 N=72 N=69
Week 12a
PASI 75 192/308 (62%) 197/309 (64%) 206/314 (66%) 188/307 (61%) –
PASI 90 109/308 (35%) 107/309 (35%) 115/314 (37%) 188/307 (61%) – –
PASI 100 43/308 (14%) 43/309 (14%) 37/314 (12%) 38/307 (12%) – –
PGA 0/1 182/308 (59%) 179/309 (58%) 186/314 (59%) 168/307 (55%) – –
Week 28a,b
PASI 75 236/298 (79%) 229/299 (77%) 217/299 (73%) 216/294 (73%) 50/72 (69%) 38/69 (55%)
PASI 90 170/298 (57%) 147/299 (49%) 169/299 (57%) 161/294 (55%) 33/72 (46%) 26/69 (38%)
PASI 100 91/298 (31%) 67/299 (22%) 79/299 (26%) 66/294 (22%) 13/72 (18%) 9/69 (14%)
PGA 0/1 199/298 (67% 188/299 (64%) 207/299 (69%) 190/294 (65%) 46/72 (64%) 33/69 (48%)
Notes: aN/total, (%). b(%) is non-responder imputation.
Abbreviations: PASI, Psoriasis Area and Severity Index; PASI 75, ≥75% improvement in PASI from baseline; PASI 90, ≥90% improvement in PASI from baseline; PASI 100, 
≥100% improvement in PASI from baseline; PBO, placebo; PGA, Physician’s Global Assessment.
Table 3 Phase III clinical trial efficacy data of tildrakizumab 100 mg at week 12
Clinical 
clearance 
metric
reSURFACE 119 reSURFACE 219
Tildrakizumab 100 mg Placebo Tildrakizumab 100 mg Placebo Etanercept
N=309 N=154 N=307 N=156 N=313
PGA 0/1 149 (58%) 11 (7%) 168 (55%) 7 (4%) 149 (48%)
PASI 75 197 (64%) 9 (6%) 188 (61%) 9 (6%) 151 (48%)
PASI 90 107 (35%) 4 (3%) 188 (61%) 2 (1%) 67 (21%)
PASI 100 43 (14%) 2 (1%) 38 (12%) 0 (0%) 15 (5%)
DLQI 0/1 126 (42%) 8 (5%) 119 (40%) 12 (8%) 108 (36%)
Note: DLQI score of 0–1 indicates no impact of skin disease on quality of life.
Abbreviations: DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PASI 75, ≥75% improvement in PASI from baseline; PASI 90, ≥90% 
improvement in PASI from baseline; PASI 100, ≥100% improvement in PASI from baseline; PGA, Physician’s Global Assessment, PGA score of 0 (clear) or 1 (minimal).
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tildrakizumab group to placebo. The peak efficacy of til-
drakizumab occurred between weeks 22 and 28 in both trials.
Safety profile
In both reSURFACE trials, the proportion of subjects report-
ing at least one AE in weeks 0–12 was similar in all treatment 
groups (tildrakizumab 200 mg: 42%/49%; tildrakizumab 
100 mg: 47%/44%; placebo: 48%/55%; etanercept: 54%). 
The most common AEs in both reSURFACE trials were 
nasopharyngitis and upper respiratory tract infections. In 
reSURFACE 2, injection site erythema was more common 
in etanercept than tildrakizumab (tildrakizumab 200 mg: 1%; 
tildrakizumab 100 mg: 1%; placebo: 1%; etanercept: 9%). 
The rate of severe infections, malignancies, skin cancers, 
major cardiovascular events, and drug-related hypersensi-
tivity reactions was low in both studies, and there was no 
significant difference between the active treatment groups. 
Discontinuation due to AEs was not frequently reported. The 
overall rate of SAEs in the first 12 weeks was low and com-
parable among the treatment groups (tildrakizumab 200 mg: 
3%/2%; tildrakizumab 100 mg: 2%/1%; placebo: 1%/3%; 
etanercept: 2%). One death occurred in reSURFACE 2 in a 
subject with alcoholic cardiomyopathy and steatohepatitis; 
this patient completed part 1 only, with the last date of study 
medication on day 30, and the death occurring on day 96, 
though the cause of death was not determined.
Quality of life
In concordance with clinical improvements, there were 
significant improvements in mean changes in DLQI for all 
tildrakizumab-treated groups in the reSURFACE trials. Prior 
to treatment, the average baseline DLQI score for participants 
was 13–15, indicating severe impact. There was significantly 
greater number of subjects treated with either dose of til-
drakizumab reporting DLQI scores of 0 or 1 (meaning no 
impact of skin disease on quality of life) when compared with 
placebo at 12 weeks (reSURFACE 1: 42% and 44% vs 5%; 
P<0.001; reSURFACE 2: 40% and 47% vs 8%, P<0.001). 
The proportion of tildrakizumab-treated subjects achieving 
these scores increased at week 28 (100 mg: 52%; 200 mg: 
57%; placebo to 100 mg: 52%; placebo to 200 mg: 56%). 
In the reSURFACE 2 trial, tildrakizumab 200 mg was asso-
ciated with significantly higher rates of patients achieving 
DLQI scores of 0/1 at week 12 compared to etanercept 50 mg 
(47% vs 36%; P=0.0029). DLQI scores of either 0 or 1 at 
week 28 were achieved by a significantly greater proportion 
of patients in both the tildrakizumab groups compared to 
patients treated with etanercept (100 mg: 54% (P=0.0003); 
200 mg: 65% (P<0.0001) vs 39%.
Full results from extension studies of the original reSUR-
FACE studies have not yet been reported.
Tildrakizumab compared to other 
biologics for psoriasis
With regard to efficacy, the class of newer biologic agents 
targeting IL-17 or IL-23 was all highly effective for psoriasis 
and are superior to older biologic agents targeting TNF-α. In 
clinical trials, tildrakizumab demonstrated superior efficacy 
over an anti-TNF-α agent, etanercept (Table 3).19 However, 
when compared with newer biologic agents, the efficacy data 
from tildrakizumab is less favorable. Within the class of IL-
23p19 inhibitors, and also in comparison to IL-17 inhibitors, 
tildrakizumab appears to be the least efficacious as measured 
by PASI scores, though no head-to-head studies comparing 
these biologics are yet available (Table 4).
Table 4 Efficacy of biologics targeting IL-23p19 and IL-17/17R for 
plaque psoriasis
Biologic Dose and 
frequency
Pasi75a Pasi90a Pasi100a
IL-23p19 inhibitors
 Guselkumab20,21 100 mg every 
8 weeks
  VOYAGE I 91% 73% 37%
  VOYAGE II 86% 70% 34%
 Tildrakizumab19 100 mg every 
12 weeks
  RESURFACE I 64% 35% 14%
  RESURFACE 2 61% 39% 12%
 Risankizumabb 150 mg every 
12 weeks
  ultIMMa-1 – 75% 36%
  ultIMMa-2 – 75% 51%
  iMMvent – 72% 40%
  iMMhance 89% 73% 47%
IL-17/17R inhibitors
 Brodalumab22,23 210 mg every 
2 weeks
  AMAGINE-1 83% 70% 42%
  AMAGINE-2 86% – 44%
  AMAGINE-3 85% – 37%
 Secukinumab24 300 mg every 
4 weeks
  ERASURE 82% 59% 29%
  FIXTURE 77% 54% 24%
 Ixekizumab25 80 mg every 
4 weeks
  UNCOVER-1 83% 65% 34%
  UNCOVER-2 78% 60% 31%
  UNCOVER-3 84% 65% 35%
Notes: aAll PASI measured at 12 weeks with the exception of guselkumab and 
risankizumab, which are measured at 16 weeks. bNot approved by the US Food and 
Drug Administration for the treatment of psoriasis.
Abbreviations: PASI, Psoriasis Area and Severity Index; PASI75, ≥75% improvement 
in PASI from baseline; PASI90, ≥90% improvement in PASI from baseline; PASI 100, 
≥100% improvement in PASI from baseline.
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From a safety standpoint, there is evidence for a favor-
able safety profile of tildrakizumab. Tildrakizumab’s safety 
profile is primarily characterized by non-serious AEs; naso-
pharyngitis and upper respiratory tract infections were the 
most common AEs in clinical trials. The dosing profile of 
tildrakizumab is also highly favorable, with maintenance 
dosing only once every 12 weeks. This is tied for the lowest 
frequency of any biologic currently approved for psoriasis, 
with the other being ustekinumab.
Use in other diseases
In addition to psoriasis, the IL-23, IL-17, and TNF pathways 
are implicated as important to the pathogenesis of psoriatic 
arthritis and axial spondyloarthropathies.8 Tildrakizumab 
is under investigation in Phase II clinical trials for anky-
losing spondylitis (NCT02980705) and psoriatic arthritis 
(NCT02980692).
Summary
Tildrakizumab is an IL-23p19 subunit inhibitor approved 
for use in adults with moderate-to-severe plaque psoriasis. 
FDA approval of tildrakizumab was based on evidence from 
several key clinical trials. A Phase I randomized placebo-con-
trolled proof-of-concept study showed that IV tildrakizumab 
at doses of 0.05–10 mg/kg produced clinical improvement in 
patients with psoriasis.13 Tildrakizumab also demonstrated 
significant improvement in the histological measures of 
psoriasis.13 A dose range finding Phase IIb study led to the 
testing of tildrakizumab 100 and 200 mg.10 Both Phase III 
studies met the primary efficacy endpoints, demonstrating 
significant clinical improvement with tildrakizumab (100 
and 200 mg) compared to placebo as measured by PASI 75 
response and PGA of 0/1 after the initial two doses.19 Long-
term safety and efficacy data, not only from tildrakizumab 
but also from the many other new biologics targeting IL-17 
and IL-23, are needed to establish the role of tildrakizumab 
in the therapeutic armamentarium for psoriasis.
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